OPGN - OpGen, Inc.
| Previous Close | 1.6500 |
| Open | 1.8000 |
| Bid | 1.7300 x 2900 |
| Ask | 1.7400 x 900 |
| Day's Range | 1.6700 - 1.8200 |
| 52 Week Range | 0.9200 - 34.5200 |
| Volume | 1,113,998 |
| Avg. Volume | 735,950 |
| Market Cap | 9.574M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.7200 |
| Earnings Date | Feb 23, 2020 - Feb 27, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Zacks
Teladoc to Buy InTouch Health, Expand Reach in Virtual Care
Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.
- GlobeNewswire
OpGen Provides Update on Curetis Group Business Receiving U.S. FDA 510(k) Clearance of its Unyvero LRT for BAL Specimens
- Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. GAITHERSBURG, Md., Dec. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen. On December 20, 2019 Curetis announced that the Company has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its Unyvero LRT Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL) samples to diagnose lower respiratory tract infections such as pneumonia.
- Zacks
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
- Zacks
Adopt Rising P/E Technique With These 5 Top-Ranked Stocks
What bargain hunting? Stocks with a rising P/E can also be worth buying too.
- GlobeNewswire
OpGen Provides Curetis Group Business Update and Announces Completion of Key Milestones in Planned Business Combination
OpGen, Inc. (OPGN) today provided a business update for the Curetis Group and announced that key milestones in the planned business combination have been achieved. Curetis recently announced that it has filed its formal response to the FDA’s Additional Information Request letter regarding Curetis’ filing for 510(k) clearance of the Unyvero LRT – Lower Respiratory Tract Application Cartridge for bronchoalveolar lavage (BAL) samples. Curetis now expects a near term clearance decision.
- GlobeNewswire
OpGen Products in Development to Address “Urgent Threat” Pathogens Highlighted in New CDC Report on Antibiotic Resistance Threats
OpGen, Inc. (OPGN) announced today that the Center for Disease Control (CDC) has released updated data increasing the number of deaths in the United States (U.S.) from antibiotic-resistant bacteria and fungi, and highlighting the continuing threat of rising antibiotic resistance. According to the CDC, these pathogens cause more than 2.8 million infections and 35,000 deaths in the U.S. each year.
- Thomson Reuters StreetEvents
Edited Transcript of OPGN earnings conference call or presentation 6-Nov-19 9:30pm GMT
Q3 2019 OpGen Inc Earnings Call
- Zacks
OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -28.46% and -28.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
OpGen Reports Third Quarter 2019 Financial Results and Provides Business Update
22% Revenue Increase Year-to-Date Update on Announced Agreement to Combine Business with Curetis Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md.,.
- GlobeNewswire
OpGen Provides Update on Curetis Group Company Ares Genetics Business
OpGen, Inc. (OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On October 28, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”) has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST).
- Zacks
Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
OpGen Announces Date of Third Quarter 2019 Financial Results Conference Call
GAITHERSBURG, Md., Oct. 29, 2019 -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its third quarter 2019 financial results after the close of the U.S..
- GlobeNewswire
OpGen Announces Closing of $9.4 Million Underwritten Public Offering
OpGen, Inc. (OPGN) today announced the closing of its previously announced underwritten public offering of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit, raising gross proceeds of approximately $9.4 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriter a 30-day option to purchase up to an additional 705,000 shares of common stock and/or common warrants to purchase up to 705,000 shares of common stock.
- Benzinga
The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
- Benzinga
The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...
- GlobeNewswire
OpGen Announces Pricing of $9.4 Million Underwritten Offering
OpGen, Inc. (OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of $2.00 per unit. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. OpGen expects to receive aggregate gross proceeds of $9.4 million from the offering, prior to deducting underwriting discounts and commissions and other estimated offering expenses.
- GlobeNewswire
U.S. Patent Allowed Covering Acuitas Lighthouse® Software
OpGen, Inc. (OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent covering the Lighthouse Profiling technology used in the company’s software for tracking antimicrobial resistant pathogens. Patent application US 20160085912A1 “Systems, Apparatus, and Methods for Generating and Analyzing Resistome Profiles” covers the use of the company’s Acuitas Lighthouse® Software for real-time monitoring of superbug infections and other multi-drug resistant infections. The Lighthouse Software was developed for use with the Acuitas® AMR Gene Panel for testing bacterial isolates.
- GlobeNewswire
OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections
The data demonstrate the concordance of Acuitas AMR Gene Panel results with conventional urine culture and the agreement with whole genome sequencing for the detection of a broad set of resistance genes that span nine antibiotic classes. Data showing antibiotic resistance predictive alignment with antibiotic susceptibility testing were also presented at the meeting.
- GlobeNewswire
OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019
OpGen’s Director of Clinical Laboratory, Dr. Jamie Lemon, Ph.D., D(ABMM), will present during the session “Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 2,” which will occur in Ballroom ABC on Saturday, October 5 from 8:00AM ET - 9:00AM ET. Dr. Lemon’s portion of the program will focus on OpGen’s Acuitas AMR Gene Panel and Acuitas Lighthouse Software, proprietary solutions in development which combine the power of genomics and informatics to inform antibiotic decision-making.
- GlobeNewswire
OpGen Provides update on Curetis Group’s R&D Collaboration
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb.
- Thomson Reuters StreetEvents
Edited Transcript of OPGN earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 OpGen Inc Earnings Call
- Benzinga
New Month, New Market: Resetting For September
Even though it’s a shortened trading week in the States thanks to the Labor Day holiday, the first days of September have felt like a fresh start. That might be a good or bad thing depending on how you ...
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For September 5, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Slack Technologies (NYSE: WORK ) shares were ...
- Benzinga
OpGen To Merge With German Molecular Diagnostics Company Curetis In $24M Deal
OpGen, a precision medicine company that uses molecular diagnostics and informatics to help combat infectious disease, announced a definitive agreement to acquire Curetis GmbHm — a wholly owned subsidiary of Curetis, which owns the Curetis Group business. The deal provides for Curetis receiving 2.66 million new shares of OpGen, representing about 72.5% of outstanding shares, valuing the combined business at about $24 million.
